{"filing":{"accession_number":"0001193125-26-265804","cik":"0001707502","ticker":"SLDB","company_name":"Solid Biosciences Inc.","form":"8-K","filing_date":"2026-06-10","report_date":null,"primary_document":"sldb-20260610.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1707502/000119312526265804/sldb-20260610.htm"},"events":[{"id":5647,"run_id":4950,"accession_number":"0001193125-26-265804","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"This Item 5.07 disclosure reports the results of Solid Biosciences' Annual Meeting of Stockholders held on June 10, 2026, covering five matters: election of Class II directors (Clare Kahn, Adam Stone, Lynne Sullivan), ratification of Class I director Ilan Ganot, ratification of PricewaterhouseCoopers LLP as independent auditor, approval of a Share Increase Amendment (doubling authorized common shares from 240M to 480M), and advisory approval of named executive officer compensation. The filing includes detailed vote tallies for each matter, confirming the core purpose of Item 5.07 shareholder vote result disclosure.","company_name":"Solid Biosciences Inc.","ticker":"SLDB","filing_date":"2026-06-10","form":"8-K","submitted_at":null,"items":[{"id":5810,"accession_number":"0001193125-26-265804","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"This Item 5.07 disclosure reports the results of Solid Biosciences' Annual Meeting of Stockholders held on June 10, 2026, covering five matters: election of Class II directors (Clare Kahn, Adam Stone, Lynne Sullivan), ratification of Class I director Ilan Ganot, ratification of PricewaterhouseCoopers LLP as independent auditor, approval of a Share Increase Amendment (doubling authorized common shares from 240M to 480M), and advisory approval of named executive officer compensation. The filing includes detailed vote tallies for each matter, confirming the core purpose of Item 5.07 shareholder vote result disclosure.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-10T20:07:09.596277+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":5810,"accession_number":"0001193125-26-265804","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"This Item 5.07 disclosure reports the results of Solid Biosciences' Annual Meeting of Stockholders held on June 10, 2026, covering five matters: election of Class II directors (Clare Kahn, Adam Stone, Lynne Sullivan), ratification of Class I director Ilan Ganot, ratification of PricewaterhouseCoopers LLP as independent auditor, approval of a Share Increase Amendment (doubling authorized common shares from 240M to 480M), and advisory approval of named executive officer compensation. The filing includes detailed vote tallies for each matter, confirming the core purpose of Item 5.07 shareholder vote result disclosure.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-10T20:07:09.596277+00:00","company_name":"Solid Biosciences Inc.","ticker":"SLDB","filing_date":"2026-06-10"}]}